March 2005
Worldwide Biotech;Mar2005, Vol. 17 Issue 3, p6
Trade Publication
Announces the drug discovery contract between Argenta Discovery Ltd. and Novartis in March 2005. Terms of the agreement; Remarks from Argenta CEO Chris Ashton on the collaboration; Efforts of the companies to develop diabetes therapies; Background of Argenta Discovery Ltd.


Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld International;5/27/2009, Vol. 14 Issue 21, p6 

    This section offers news briefs on the biotechnology industry. The drug discovery agreement between Argenta Discovery Ltd. and Genentech Inc. has been extended for two years. The Australian government has increased its research and development spending by 25 percent to A$8.58 billion in the...

  • Argenta to Collaborate with Armedis Pharmaceuticals.  // Drug Discovery & Development;Jul/Aug2002, Vol. 5 Issue 7, p19 

    Reports on the drug discovery collaboration between Argenta Discovery Ltd. and Amedis Pharmaceuticals Ltd. in Great Britain.

  • Alliances/Collaboration. Holland-Moritz, Pam // Drug Discovery & Development;Nov2003, Vol. 6 Issue 11, p20 

    Reports on alliances and collaborations in the drug development and discovery industry, as of November 2003. Progress made on Argenta Discovery Ltd.'s collaboration with Pharmagene PLC on Pharmagene's R1 irritable bowel syndrome therapeutic program; Agilent Technologies Inc.'s entry into a...

  • Biotech--Biotech Collaborations: Modified Agreements: Oct. 18 - Dec. 19, 2007.  // BioWorld Financial Watch;12/31/2007, Vol. 15 Issue 53, p13 

    The article offers information on several modified and terminated agreements established between biotechnology companies. Argenta Discovery Ltd. and Genentech Inc. have extended their contract drug discovery agreement for two more years. Dyax Corp. and ImClone Systems Inc. have expanded their...

  • Novartis Drops Termination Clause in Morphosys Pact. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p5 

    The article reports on the decision of Novartis AG to remove an early termination clause in the antibody development deal it entered with Morphosys AG. As a result, the deal originally signed in December 2007, is now set to run until 2017. The clause in question will permit the company to quit...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p2 

    This section offers news briefs on the biotechnology industries. A drug discovery agreement between Argenta Discovery Ltd. and Genentech Inc. has been extended for two years. A 50.1 percent interest in Arana Therapeutics Limited's shares was acquired by Cephalon International Holdings Inc., a...

  • Power of Defined Groups. Dickey, Chris // Drug Discovery & Development;Aug2003, Vol. 6 Issue 8, p11 

    Editorial. Focuses on the tyrosine kinase inhibitor Gleevec, developed by Novartis AG for cancer. Clinical trials of the drug; Commercial viability of Gleevec.

  • MS Therapy Shows Sustained Benefits.  // Drug Discovery & Development;May2008, Vol. 11 Issue 5, p30 

    The article evaluates the oral therapy FTY720 (fingolimod) from Novartis AG.

  • OTHER NEWS TO NOTE.  // BioWorld Today;10/2/2007, Vol. 18 Issue 191, p2 

    This section offers news briefs related to biotechnology. Argenta Discovery Ltd. has entered a fee-for-service contract drug discovery collaboration with CellCentric Ltd. in Great Britain. Jerusalem-based BioLineRx Ltd. has signed a worldwide exclusive license agreement with Yeda Research and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics